NGFN-PLUS
SNP array for atherosclerosis Development of innovative diagnostics
| Coordinator: | Dr. Ulf Steller (EUROIMMUN AG) | |
| Institution: | EUROIMMUN AG | |
| Homepage: | www.euroimmun.de |
The present subproject amalgamates latest technical progress of diagnostic microarray
development with recently obtained SNP identification from large genome-wide studies in
relation to cardiovascular disease and envisages to construct, prove, and customize a
new diagnostic array for early detection and prognosis of cardiovascular risk. Within this sub-project the first goal is to develop a diagnostic microarray system based on approximately 30 SNP candidates (ca. 10 from BioChancePlus study, ca. 10 from EU project Cardiogenics and ca. 10 from literature). All SNPs to be implemented are strongly associated with increased risk of early myocardial infarction and currently undergo the legal protection processes at the respective universities and Euroimmun. For SNP genotyping the diagnostic microarray platform developed by Euroimmun within the BioChancePlus-project 0313371 (cooperative project between EUROIMMUN and University of Mainz; Lübeck and Munich) will be used. In the first step all gene fragments of interest are amplified. The PCR products serve as a template for the enzymatic SNP-specific labelling step that incooperates fluorescence molecules into the nucleic acid fragments. Finally the products from each sample are hybridised with the microarray on the multiple array slide consisting. For final readout, multiple slides are scanned simultaneously in a specific scanner also developed as part of the BioChancePlus project.
The present subproject amalgamates latest technical progress of diagnostic microarray development with recently obtained SNP identification from large genome-wide studies in relation to cardiovascular disease and envisages to construct, prove, and customize a new diagnostic array for early detection and prognosis of cardiovascular risk. As a result of its multidisciplinary nature, this academic consortium and its private partners will contribute to the development of innovative diagnostic tools. The focus of this transfer-project is on the translation of complex scientific genomic data into clinical application, specifically the development and validation of innovative diagnostics and – finally – its commercialization.
Further Coordinators:
development with recently obtained SNP identification from large genome-wide studies in
relation to cardiovascular disease and envisages to construct, prove, and customize a
new diagnostic array for early detection and prognosis of cardiovascular risk. Within this sub-project the first goal is to develop a diagnostic microarray system based on approximately 30 SNP candidates (ca. 10 from BioChancePlus study, ca. 10 from EU project Cardiogenics and ca. 10 from literature). All SNPs to be implemented are strongly associated with increased risk of early myocardial infarction and currently undergo the legal protection processes at the respective universities and Euroimmun. For SNP genotyping the diagnostic microarray platform developed by Euroimmun within the BioChancePlus-project 0313371 (cooperative project between EUROIMMUN and University of Mainz; Lübeck and Munich) will be used. In the first step all gene fragments of interest are amplified. The PCR products serve as a template for the enzymatic SNP-specific labelling step that incooperates fluorescence molecules into the nucleic acid fragments. Finally the products from each sample are hybridised with the microarray on the multiple array slide consisting. For final readout, multiple slides are scanned simultaneously in a specific scanner also developed as part of the BioChancePlus project.
The present subproject amalgamates latest technical progress of diagnostic microarray development with recently obtained SNP identification from large genome-wide studies in relation to cardiovascular disease and envisages to construct, prove, and customize a new diagnostic array for early detection and prognosis of cardiovascular risk. As a result of its multidisciplinary nature, this academic consortium and its private partners will contribute to the development of innovative diagnostic tools. The focus of this transfer-project is on the translation of complex scientific genomic data into clinical application, specifically the development and validation of innovative diagnostics and – finally – its commercialization.
KTT
MEDIA
CURRENT
NGFN-MEETING-2012
NGFN- MEETING
NGFN1&2
LINKS